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Biocatalysis is an invaluable tool for the synthesis of many active pharmaceutical ingredients1,2. Enzymatic 
reactions are frequently performed in batch, but continuous biocatalysis is gaining interest in industry3, not least 
because it would allow better integration of chemical and enzymatic reaction steps4. However, selecting a 
suitable reactor configuration for continuous biocatalysis is often challenging due to the common limitations of 
enzymes, such as poor kinetic constants towards industrially relevant substrates, substrate/product inhibition, 
the need for an aqueous reaction environment and/or pH control. For this reason, we have recently developed a 
tool5 that presents a variety of reactor configurations, combining continuously stirred tank reactors (CSTRs) and 
continuous plug-flow reactors (CPFRs), to overcome the aforementioned limitations and facilitate reactor 
selection. However, the continued development of protein engineering technologies6,7 has revealed one of the 
strongest advantages of biocatalysis over chemocatalysis, namely that the properties of the catalyst can be 
modified to remove limitations and better suit industrial production processes.8,9 In this presentation we highlight 
how protein engineering, guided by process-specific targets, can streamline process development. For example, 
reducing product inhibition by protein engineering could allow operation in a single CPFR where the possibility 
of complete conversion greatly simplifies downstream processing, improving the tolerance of enzymes towards 
organic solvents could allow water-free operation without mass transfer limitations between phases and 
improving pH tolerance could remove the need for acid/base addition to combat pH changes during operation. 
Such changes to the catalyst could greatly facilitate process development in an industry where reduction of 
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